Spiro-heteroazolones for treatment of diabetes complications
CA 1292992 C · Owner: Lipinski, Christopher Andrew · Inventors: Lipinski, Christopher Andrew
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
4680-338, Abstract, Spiro-heteroazolones of the formula below are disclosed which are useful as aldose reductase inhibitors and as therapeutic agents for the treatment of complications arising from diabetes: I, or a pharmaceutically acceptable salt thereof wherein A is methylene, hydroxy-, methylene or methine; Y is methylene, alkylmethylene methine or alkyl-, methine, wherein alkyl in each instance has 1-4 carbon atoms; with the proviso that when A is methine, Y is methine or alkylmethine; Z is oxygen sulfur, or nitrogen substituted by hydrogen; Q is nitrogen or nitrogen-N-oxide; and X is in the 3'-position and is hydrogen halo, alkyl, alkoxy having 1-4 carbon, atoms alkylthio, …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Granted December 10, 1991. A Canadian patent filed before October 1, 1989 lasted 17 years from grant, so its term ended December 10, 2008.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.